An observational study in Unknown Primary Tumors and DNA Methylation, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Sun Yat-sen University · Observational
This study aims to initially utilize machine learning on pan-cancer DNA methylation data from public databases to construct a DNA methylation classification model (PaCIFiC-CUP, pan-cancer integrated fingerprinting classifier of CUP) for diagnosing various types of cancer, particularly the primary site of cancer of unknown primary. The goal is to achieve diagnosis of cancer pathology type by analyzing the DNA methylation patterns of cancer specimens, thereby guiding subsequent precision treatment for cancer.
The study population consists of patients diagnosed with CUP who meet the inclusion and exclusion criteria.
Exclusion Criteria:
These patients with cancer of unknown primary received site-specific therapy that matched the particular site predicted by the DNA methylation classifier.
These patients with cancer of unknown primary received empirical therapy that didn't match the particular site predicted by the DNA methylation classifier.
Overall Survival
Overall survival refers to the length of time that a person lives after being diagnosed with cancer of unknown primary, without regard to any specific cause of death.
Time frame: From date of diagnosis until the date of death from any cause, assessed up to 24 months
Progression-Free Survival
Progression-Free Survival refers to the length of time during which a patient with cancer of unknown primary remains alive without any signs or symptoms of disease progression
Time frame: From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sun Yat-sen University